SENS
Senseonics Holdings, Inc.

Senseonics Holdings, Inc.SENS

Healthcare · Medical Devices
10.06USD
+2.86%
Sep 23, 2026
SENS overview ready
SENS is a direct, relatively pure-play CGM participant differentiated by long-duration implantable sensors rather than the disposable wearable sensors that dominate the category.
Strong narrative exposure
Exposed to the Metabolic Disease Treatment Expansion narrative through Continuous Glucose Monitoring Penetration and Long-Duration Sensors — pure play.
Advancing price action
Longer-term context reads early recovery, with a near-term setup of daily advance.
Demanding valuation
The price embeds expectations that run ahead of the growth it delivers per turn of revenue multiple.
Unremarkable fundamentals
Primary risk
Regulatory approval and compliance risks.
Market Sep 22Filing Jun 30Price action Sep 22Research Sep 15

Conviction Level

NarrativeHeat5.8ThemeHeat6.4PriceAction9.1Valuation0.9CompanyPosition7.3
Price
Loading price history…

Price Action

Advancing price action
Longer-term context reads early recovery, with a near-term setup of daily advance.
EntryConstructive

Structure is constructive on both timeframes without excessive extension — a reasonable entry location.

Key Financials

Market Cap
$531.9M
Avg Volume (60D)
716.6K
60 sessions
Revenue Growth YoY
+56.9%
FY2025 vs FY2024
Gross Margin
+54.9%
Trailing twelve months
Operating Margin
-223.2%
Trailing twelve months
Free Cash Flow Yield
-18.2%
Distance from 200DMA
+47.0%
Next Earnings
2026-11-04
P/E
N/M
EV / Sales
9.2x
Market metrics as of Sep 22, 2026
Financial results for the period ended Jun 30, 2026
Filed balance-sheet data as of Jun 30, 2026

Fundamentals & Valuation

Two of the three valuation perspectives say expensive; own history is the dissenting view.
Senseonics Holdings, Inc. has an Expensive valuation stance because the price embeds expectations that run ahead of the growth it delivers per turn of revenue multiple.

Company Research

Thesis
SENS is a direct, relatively pure-play CGM participant differentiated by long-duration implantable sensors rather than the disposable wearable sensors that dominate the category.
Opportunity
Moderate opportunity
Growing use of continuous glucose monitoring across diabetes care, supported by clinical-guideline adoption, payer and provider access, integration with insulin-delivery systems, and product innovation that lowers wear-and-replacement burden through longer-duration sensors.
Key risk
Regulatory approval and compliance risks.

Narrative & Theme

Metabolic Disease Treatment Expansion
Part of Continuous Glucose Monitoring Penetration and Long-Duration Sensors, with strong fit.
Senseonics is a genuine direct beneficiary of wider CGM adoption in diabetes management, which fits the promoted Metabolic Disease Treatment Expansion narrative but is not represented by either currently listed active theme.
Narrative HeatNeutral5.8 / 10
Theme HeatNeutral6.4 / 10
This is the company’s own research reading. The canonical heat measurement for this story has not run.

Business & Markets

Healthcare · Medical Devices
What they do

Senseonics Holdings, Inc. develops and manufactures implantable continuous glucose monitoring (CGM) systems for people with diabetes, combining under-the-skin sensors with smart transmitters and mobile apps for real-time glucose monitoring.

How it earns

The company generates revenue primarily through the sale of its CGM devices and related components to healthcare providers and patients.

Products & services
Eversense
Eversense XL
Eversense E3
Eversense 365
Customers & end markets
People with diabetes
Healthcare providers
Market position

Niche player specializing in implantable CGM technology within the broader diabetes monitoring market.

Demand drivers
Low cyclicality

Demand for diabetes management devices is relatively stable and driven by chronic health needs rather than economic cycles.